RARITAN, N.J., July 9 /PRNewswire/ -- Zeus Scientific, Inc. today announced its intention to offer a rapid nasal screening test for methicillin-resistant Staphylococcus aureus (MRSA). The test is based upon Zeus’ own proprietary technology utilizing the enrichment and nucleic acid amplification of a target pathogen.
Available through the Zeus worldwide distribution network, the new MRSA test will enable healthcare professionals to identify carriers of this pathogen within two hours. Published studies have shown that time-to-results is critical in demonstrating a reduction in MRSA hospital infection rates.
In addition to significantly improving assay performance over other technologies in this product space, the nasal MRSA test will be offered as a low cost alternative to the two currently FDA approved MRSA PCR products without sacrificing time to results or performance.
Zeus is uniquely positioned in this area through relevant patent filings, further expanding its Intellectual Property portfolio and providing new product protection.
About Zeus Scientific, Inc.
Zeus Scientific, Inc. is a global leader in the field of clinical diagnostics products. Zeus has a developing pipeline of innovative, high quality, and cost-effective diagnostic solutions geared toward the enhancement of patient care. Zeus’ products are marketed and distributed worldwide through a vast network of quality distribution partnerships.
For additional information about the nasal screening test for MRSA, please contact Zeus at 908-526-3744 or visit our web site at www.zeusscientific.com.
CONTACT: James S. Vingara of Zeus Scientific, Inc., +1-908-526-3744,
jvingara@zeusscientific.com
Web site: http://www.zeusscientific.com/
